CardieX (ASX:CDX) - CEO & Managing Director, Craig Cooper
CEO & Managing Director, Craig Cooper
Source: Craig Cooper
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • CardieX’s (CDX) subsidiary, ATCOR, has been granted a new patent by the European Patent Office (EPO) for its SphygmoCor technology
  • This technology enables non-invasive measurement of artery stiffness through central arterial pressure waveform and blood pressure analysis
  • The new patent further protects CardieX’s intellectual property (IP), specifically covering the non-invasive measurement of the heart’s pressure
  • The grant of the European patent follows on from similar patents already granted in the U.S. and Japan in 2016
  • CardieX is up a healthy 16.3 per cent and shares are trading for 5.7 cents

CardieX’s (CDX) subsidiary, ATCOR, has been granted a new patent by the European Patent Office (EPO) for its SphygmoCor technology.

The SphygmoCor technology enables non-invasive measurement of artery stiffness through central arterial pressure waveform and blood pressure analysis.

It has more than 4500 installations worldwide and is used by major pharmaceutical companies and research institutions such as The Mayo Clinic, Stanford University, and Johns Hopkins.

The new patent further protects CardieX’s intellectual property (IP), specifically covering the non-invasive measurement of the heart’s pressure and waveform.

This patent provides a non-invasive, simple, and operator-independent tool to clinically diagnose the cardiovascular system and estimate the risk of having heart disease.

The granting of the European patent follows on from similar patents already granted in the United States and Japan in 2016.

“We are very pleased to be granted this new patent to protect our IP in Europe,” CEO and Managing Director Craig Cooper said.

“Of great significance is the findings of the examining officers from the EPO, which were similar to the findings we received from examiners in the U.S. in 2016 – that there are substantial differences in respect of any other existing patents – further demonstrating and validating the uniqueness of our technology,” he added.

CardieX is up a healthy 16.3 per cent and shares are trading for 5.7 cents at 2:00 pm AEST.

CDX by the numbers
More From The Market Herald

" Race Oncology (ASX:RAC) reports $1.8m in cash outflows

Race Oncology (ASX:RAC) reports $1.8 million in cash outflows
Imugene (ASX:IMU) - CEO, Leslie Chong

" Imugene (ASX:IMU) signs clinical trial agreement with Roche for lung cancer

Imugene (ASX:IMU) signs a clinical trial supply agreement with Roche to evaluate the combination of treatments…
Fiji Kava (ASZ:FIJ) - CEO and Managing Director, Dr Anthony Noble

" Fiji Kava (ASX:FIJ) hits quarterly revenue record

Fiji Kava (ASX:FIJ) has tabled a record quarterly revenue of $476,531 for the December quarter, up…